admin

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for …

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS Read More »

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments. NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human …

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases Read More »

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction

Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a …

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction Read More »

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members

New board members bring a wealth of financial, strategy and global health expertise.   NORTH BRUNSWICK, N.J., February 17, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris …

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members Read More »

Kris Vinckier

Kris Vinckier is a Director and Co-Founder of Paradox Investment Management BV, which manages the investment fund, Paradox Investment Network BV, a Private Privak under Belgian Law. Mr. Vinckier is a seasoned executive in the financial and commercial services sector, who currently serves as the Head of Business Strategy Life and Employee Benefits for Vivium, …

Kris Vinckier Read More »

Kerry Maguire, DDS, MSPH

Dr. Kerry Maguire is a healthcare executive who most recently served as the Vice-President for Clinical Operations at the Forsyth Institute in Cambridge, MA. As a public health professional, her focus has been on health disparities of vulnerable populations, primarily children and people living with HIV.   Kerry has held faculty roles at Tufts University School …

Kerry Maguire, DDS, MSPH Read More »

Associate Researcher

ASSOCIATE RESEARCHER Successful candidate will have prior experience with varied biochemical analytical methods such as ELISA and HPLC. This role will work in a team with Research Scientists in the conduct of key activities directed toward the development of the therapeutic pipeline products. RESPONSIBILITIES: General laboratory support activities including ordering supplies, maintenance of equipment and …

Associate Researcher Read More »

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022

NORTH BRUNSWICK, N.J., January 24, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, reports highlights from its recent shareholder meeting. Highlights Include:  Clinical: Completed second clinical study in the EU and planning US phase 2/3 program …

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022 Read More »

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

NORTH BRUNSWICK, N.J., October 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announces that it was selected to present at the MACRO Trends Investor Conference on November 12, 2021. Co-founders Valerie Ceva, COO, and …

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium Read More »

November 12, 2021: Belgium MACRO Trends Investors Conference

BioAegis co-founders were selected to present at the upcoming MACRO Trends Investors Conference in Belgium. The presentation, “Conquering Pneumonia and Systemic Inflammation,” will highlight BioAegis’ novel, host-directed treatment. About MACRO Trends MACRO Trends is a Dutch Investment advisory firm centered around a regularly published magazine edited by Brecht Arnaert, a monetary expert at the Rey …

November 12, 2021: Belgium MACRO Trends Investors Conference Read More »